V1

Vicarious Surgical (based in the Waltham, Massachusetts area; public via a 2021 SPAC merger as NYSE: RBOT) is developing the V1, a single-port surgical robot concept built around a 9-degree-of-freedom human-like instrument and an immersive virtual-reality-style surgeon interface meant to transport the surgeon inside the patient. The headline finding is the company's distress: its first-quarter 2026 Form 10-Q carries an explicit going-concern substantial-doubt, with cash and short-term investments of $3.682 million as of March 31, 2026 and a stated runway only through the second quarter of 2026, a quarterly net loss of $7.329 million, and zero revenue ever, since the product has never been commercialized; NYSE trading was suspended on March 3, 2026 with delisting proceedings commenced, and the stock moved to the OTCQB on March 24, 2026 after a reverse split used as a survival maneuver. The registry records V1 at research maturity, because it has no FDA clearance and not even an FDA submission yet, with its planned De Novo pathway and first-in-human study repeatedly delayed, so under the verified-vs-claimed framework no clearance means research-tier regardless of years of demonstrations, and the differentiators remain engineering concepts in animal-lab and design-freeze stage. The lifecycle is recorded as active but materially at risk of becoming discontinued within the cash-runway window, and this record should be re-verified within weeks given the Q2-2026 cliff.

V1's price is not publicly disclosed. DEPLOY has no verified price on record for V1 from Vicarious Surgical. Physical-AI systems like this are often sold through enterprise contracts or operated as a service rather than at a public list price; check the manufacturer for the latest.

V1 is at the research stage: it exists, but DEPLOY has no verified real-world deployment on record. Manufacturer capability claims should be read as claims pending independent verification.

V1 is made by Vicarious Surgical, based in Waltham, Massachusetts, USA, founded in 2014.

V1 is at research stage and is not yet available for sale.

On the DEPLOY registry, comparable surgical robots to V1 include da Vinci (and Ion), Edge Multi-Port Surgical Robot, Edison Histotripsy System, Stryker Mako SmartRobotics.

V1 and da Vinci (and Ion) (Intuitive Surgical · 15 deployments) are both surgical robots on the DEPLOY registry. V1 has 0 verified deployments on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.

On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, V1 ranks in roughly the top 80% of surgical models tracked by the registry.

V1 is at the research stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Research stage means active development without commercial deployments on file.

No verified deployments of V1 are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.

V1 has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.